Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses

Biotechnology Journal

Volumn 8, Issue 11, 2013, Pages 1315-1322

  Lin, Shih Chang ^a   Liu, Wen Chun ^a   Lin, Yu Fen ^a   Huang, Yu Hsuan ^a   Liu, Jin Hwang ^b   Wu, Suh Chin ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adenovirus; H5N1 vaccine; Prime boost immunization; Virus like particles

Indexed keywords

ADENOVIRUS; ADENOVIRUS VECTOR; H5N1 AVIAN INFLUENZAS; HIGHLY PATHOGENIC AVIAN INFLUENZAS; NEUTRALIZING ANTIBODIES; RECOMBINANT ADENOVIRUS; VACCINATION STRATEGY; VIRUS-LIKE PARTICLES;

ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; ENCODING (SYMBOLS); IMMUNIZATION; VACCINES; VECTORS;

VIRUSES;

ADENOVIRUS VECTOR; FLAGELLIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; HOMOLOGOUS RECOMBINATION; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOUSE; MURINE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS LIKE AGENT; VIRUS STRAIN;

ADENOVIRIDAE; AVES; AVIAN INFLUENZA VIRUS; MURINAE;

ADENOVIRUS; H5N1 VACCINE; PRIME-BOOST IMMUNIZATION; VIRUS-LIKE PARTICLES;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; FLAGELLIN; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84887097336     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201300116     Document Type: Article

References (39)

1. Horimoto, T., Kawaoka, Y., Influenza: Lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 2005, 3, 591-600.
2. Tong, S., Li, Y., Rivailler, P., Conrardy, C. et al., A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. USA 2012, 109, 4269-4274.
3. Zhu, X., Yu, W., McBride, R., Li, Y. et al., Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc. Natl. Acad. Sci. USA 2013, 110, 1458-1463.
4. Lasaro, M. O., Ertl, H. C., New insights on adenovirus as vaccine vectors. Mol. Ther. Nucleic Acids 2009, 17, 1333-1339.
5. Malkevitch, N. V., Patterson, L. J., Aldrich, M. K., Wu, Y. et al., Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: Role of SIV-specific CD8+ T cell responses. Virology 2006, 353, 83-98.
6. Demberg, T., Florese, R. H., Heath, M. J., Larsen, K. et al., A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2007, 81, 3414-3427.
7. Khanam, S., Rajendra, P., Khanna, N., Swaminathan, S., An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol. 2007, 7, 10.
8. Guo, L., Zhou, H., Wang, M., Song, J. et al., A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. Vaccine 2009, 27, 5233-5238.
9. Magalhaes, I., Sizemore, D. R., Ahmed, R. K., Mueller, S. et al., rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 2008, 3, e3790.
10. Draper, S. J., Moore, A. C., Goodman, A. L., Long, C. A. et al., Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 2008, 14, 819-821.
11. Haynes, J. R., Influenza virus-like particle vaccines. Expert Rev. Vaccines 2009, 8, 435-445.
12. Pushko, P., Tumpey, T. M., Bu, F., Knell, J. et al., Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23, 5751-5759.
13. Bright, R. A., Carter, D. M., Daniluk, S., Toapanta, F. R. et al., Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25, 3871-3878.
14. Quan, F. S., Huang, C., Compans, R. W., Kang, S. M., Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81, 3514-3524.
15. Pushko, P., Tumpey, T. M., Van Hoeven, N., Belser, J. A. et al., Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25, 4283-4290.
16. Bright, R. A., Carter, D. M., Crevar, C. J., Toapanta, F. R. et al., Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3, e1501.
17. Quan, F. S., Steinhauer, D., Huang, C., Ross, T. M. et al., A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26, 3352-3361.
18. Quan, F. S., Yoo, D. G., Song, J. M., Clements, J. D. et al., Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J. Virol 2009, 83, 4489-4497.
19. Quan, F. S., Vunnava, A., Compans, R. W., Kang, S. M., Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 2010, 5, e9161.
20. Wang, B. Z., Quan, F. S., Kang, S. M., Bozja, J. et al., Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 2008, 82, 11813-11823.
21. D'Aoust, M. A., Lavoie, P. O., Couture, M. M., Trepanier, S. et al., Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 2008, 6, 930-940.
22. D'Aoust, M. A., Couture, M. M., Charland, N., Trepanier, S. et al., The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 2010, 8, 607-619.
23. Landry, N., Ward, B. J., Trepanier, S., Montomoli, E. et al., Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5, e15559.
24. Lai, J. C., Chan, W. W., Kien, F., Nicholls, J. M. et al., Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J. Gen. Virol. 2010, 91, 2322-2330.
25. Wu, C. Y., Yeh, Y. C., Yang, Y. C., Chou, C. et al., Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010, 5, e9784.
26. Giles, B. M., Ross, T. M., A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 2011, 29, 3043-3054.
27. Yondola, M. A., Fernandes, F., Belicha-Villanueva, A., Uccelini, M. et al., Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J. Virol. 2011, 85, 2480-2491.
28. Wei, H. J., Chang, W., Lin, S. C., Liu, W. C. et al., Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine 2011, 29, 7163-7172.
29. Lin, S. C., Huang, M. H., Tsou, P. C., Huang, L. M. et al., Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One 2011, 6, e20052.
30. Wei, C. J., Yassine, H. M., McTamney, P. M., Gall, J. G. et al., Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 2012, 4, 147ra114.
31. Wei, C. J., Boyington, J. C., McTamney, P. M., Kong, W. P. et al., Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329, 1060-1064.
32. Ledgerwood, J. E., Wei, C. J., Hu, Z., Gordon, I. J. et al., DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 2011, 11, 916-924.
33. Douglas, A. D., de Cassan, S. C., Dicks, M. D., Gilbert, S. C. et al., Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 2010, 28, 7167-7178.
34. Lin, S. C., Lin, Y. F., Chong, P., Wu, S. C., Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One 2012, 7, e39075.
35. Ross, T. M., Xu, Y., Bright, R. A., Robinson, H. L., C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nature Immunol. 2000, 1, 127-131.
36. Draper, S. J., Biswas, S., Spencer, A. J., Remarque, E. J. et al., Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 2010, 185, 7583-7595.
37. Sylte, M. J., Suarez, D. L., Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol. 2009, 333, 227-241.
38. Khurana, S., Chearwae, W., Castellino, F., Manischewitz, J. et al., Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2010, 2, 15ra15.
39. Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K. et al., MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 2011, 3, 85ra48.